methyl 4-(1-methyl-1H-indazol-3-yl)benzoate | 1018788-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 4-(1-methyl-1H-indazol-3-yl)benzoate
• 英文别名: Methyl 4-(1-methylindazol-3-yl)benzoate
• CAS: 1018788-82-3
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: OTPHVRHAARJPDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-(1-methyl-1H-indazol-3-yl)benzoate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以85.6%的产率得到4-(1-methyl-1H-indazol-3-yl)benzoic acid
  参考文献：
  名称：

  Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives

  摘要：

  Previously, ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist. To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compound and a series of its derivatives were synthesized and evaluated for their selective anti-PAR4 activity. Through structure-activity relationship (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification. Several new compounds with anti-PAR4 activity comparable to YD-3 were identified. Among them, ethyl 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression. On the other hand, ethyl 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid. The above findings can be used as guidelines for development of novel antiplatelet drug candidates. (c) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2007.10.070
• 作为产物：
  描述：

  methyl 4-(1H-indazol-3-yl)benzoate 、 碘甲烷 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 12.0h， 以48.9%的产率得到methyl 4-(1-methyl-1H-indazol-3-yl)benzoate
  参考文献：
  名称：

  Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives

  摘要：

  Previously, ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist. To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compound and a series of its derivatives were synthesized and evaluated for their selective anti-PAR4 activity. Through structure-activity relationship (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification. Several new compounds with anti-PAR4 activity comparable to YD-3 were identified. Among them, ethyl 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression. On the other hand, ethyl 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid. The above findings can be used as guidelines for development of novel antiplatelet drug candidates. (c) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2007.10.070

文献信息

• One-pot synthesis of 1-alkyl-1H-indazoles from 1,1-dialkylhydrazones via aryne annulation
  作者：Nataliya A. Markina、Anton V. Dubrovskiy、Richard C. Larock

  DOI：10.1039/c2ob07117g

  日期：——

  The reaction of readily accessible 1,1-dialkylhydrazones with commercially available o-(trimethylsilyl)aryl triflates provides a direct one-step route to pharmaceutically important 1-alkylindazoles. The products are obtained in high yields by one-pot NCS-chlorination/aryne annulation or Ac2O-acylation/deprotection/aromatization protocols.

  容易获得的1,1-二烷基肼酮与市售的o-(三甲基硅基)芳基三氟甲磺酸酯反应，提供了一种直接的一步法合成药物重要的1-烷基吡唑并的途径。通过一次性NCS氯化/芳烃环化或Ac2O酰化/去保护/芳香化方案，可以高产率地获得产物。
• Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives
  作者：Hua-Sin Chen、Sheng-Chu Kuo、Che-Ming Teng、Fang-Yu Lee、Jih-Pyang Wang、Yu-Chun Lee、Chiung-Wen Kuo、Ching-Che Huang、Chin-Chung Wu、Li-Jiau Huang

  DOI：10.1016/j.bmc.2007.10.070

  日期：2008.2.1

  Previously, ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist. To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compound and a series of its derivatives were synthesized and evaluated for their selective anti-PAR4 activity. Through structure-activity relationship (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification. Several new compounds with anti-PAR4 activity comparable to YD-3 were identified. Among them, ethyl 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression. On the other hand, ethyl 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid. The above findings can be used as guidelines for development of novel antiplatelet drug candidates. (c) 2008 Published by Elsevier Ltd.